Publication:
Mesenchymal Stem Cells Delivery in Individuals with Different Pathologies: Multimodal Tracking, Safety and Future Applications

dc.contributor.authorBelmar-López, Carolina
dc.contributor.authorVassaux, Georges
dc.contributor.authorMedel-Martínez, Ana
dc.contributor.authorBurnet, Jerome
dc.contributor.authorQuintanilla, Miguel
dc.contributor.authorRamón y Cajal, Santiago
dc.contributor.authorHernandez-Losa, Javier
dc.contributor.authorDe la Vieja, Antonio
dc.contributor.authorMartin-Duque, Pilar
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderGobierno de Aragón (España)
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.date.accessioned2022-04-20T09:55:48Z
dc.date.available2022-04-20T09:55:48Z
dc.date.issued2022-01-31
dc.description.abstractDue to their ease of isolation and their properties, mesenchymal stem cells (MSCs) have been widely investigated. MSCs have been proved capable of migration towards areas of inflammation, including tumors. Therefore, they have been suggested as vectors to carry therapies, specifically to neoplasias. As most of the individuals joining clinical trials that use MSCs for cancer and other pathologies are carefully recruited and do not suffer from other diseases, here we decided to study the safety and application of iv-injected MSCs in animals simultaneously induced with different inflammatory pathologies (diabetes, wound healing and tumors). We studied this by in vitro and in vivo approaches using different gene reporters (GFP, hNIS, and f-Luc) and non-invasive techniques (PET, BLI, or fluorescence). Our results found that MSCs reached different organs depending on the previously induced pathology. Moreover, we evaluated the property of MSCs to target tumors as vectors to deliver adenoviruses, including the interaction between tumor microenvironment and MSCs on their arrival. Mechanisms such as transdifferentiation, MSC fusion with cells, or paracrine processes after MSCs homing were studied, increasing the knowledge and safety of this new therapy for cancer.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis research was supported by Instituto de Salud Carlos III (ISCIII) (PI19/01007 and DTS21/00130) and by Fondo Europeo de Desarrollo Regional (Feder) “Una manera de hacer Europa”. We also thank CIBER-BBN and CIBERONC an initiative funded by the VI National R&D&i Plan 2008–2011 financed by the Instituto de Salud Carlos III (ISCIII) with the assistance of the European Regional Development Fund. This study was also partially funded by the Aragon Government (Ph.D. Grant No.r B054/12) and cofounded by Aragon/FEDER 2014–2020 “Building Europe from Aragon”. This research was funded by Spanish Ministerio de Economía y Competitividad and European Regional Development Fund (FEDER) SAF2015-69964-R, RTI2018-099343-B-100 and from the CiberOnc by Instituto de Salud Carlos III (to ADlV).es_ES
dc.format.number3es_ES
dc.format.page1682es_ES
dc.format.volume23es_ES
dc.identifier.citationInt J Mol Sci. 2022;23(3):1682.es_ES
dc.identifier.doi10.3390/ijms23031682es_ES
dc.identifier.e-issn1422-0067es_ES
dc.identifier.journalInternational Journal of Molecular Scienceses_ES
dc.identifier.pubmedID35163605es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14129
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//SAF2015-69964-R/ES/MECANISMOS MOLECULARES DEL SIMPORTADOR NIS EN FISIOPATOLOGIA DE TIROIDES Y OVARIO/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RTI2018-099343-B-100es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI19/01007es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/DTS21/00130es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/ijms23031682es_ES
dc.repisalud.centroISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC)es_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectImaging PETes_ES
dc.subjectSPECTes_ES
dc.subjectBioluminescencees_ES
dc.subjectDiabeteses_ES
dc.subjectInjuryes_ES
dc.subjectLuciferasees_ES
dc.subjectMesenchymal stem cellses_ES
dc.subjectRadioiodine therapyes_ES
dc.subjectSodium/iodide symporter (NIS)es_ES
dc.subjectTherapyes_ES
dc.subjectTransdifferentiationes_ES
dc.titleMesenchymal Stem Cells Delivery in Individuals with Different Pathologies: Multimodal Tracking, Safety and Future Applicationses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication4f2e267d-86ef-44ce-baa0-ab58dc69e6c5
relation.isAuthorOfPublication97276f84-b860-46f4-8f01-665663ea04a9
relation.isAuthorOfPublication.latestForDiscovery4f2e267d-86ef-44ce-baa0-ab58dc69e6c5
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublicationd9081f19-60cf-4e43-b80c-5f49c2e30a4d
relation.isFunderOfPublication77b2fc20-6311-4e46-98a7-83e46257b93b
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
MesenchymalStemCellsDelivery_2022.pdf
Size:
5.32 MB
Format:
Adobe Portable Document Format
Description: